Drug Trial Radar · NCT06721013
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
68
Planned (sponsor's estimate)
Start
Jul 30, 2025
Primary completion
Feb 2028
Study completion Feb 2029
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Dec 6, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the phase 1 part of this study was to evaluate how well pirtobrutinib is tolerated and what side effects may occur. The phase 2 part of the study will further investigate efficacy and safety of multiple pirtobrutinib dosages versus placebo. The study drug will be administered orally in participants with Primary Immune Thrombocytopenia (ITP). Blood tests will be performed to check how much pirtobrutinib gets into the bloodstream and how long it takes the body to eliminate it. The study will last up to approximately 16 weeks for phase 1 dose-escalation and 28 weeks for phase 2 dose-optimization, excluding screening.
Conditions
- Immune Thrombocytopenia (ITP)
Interventions
PirtobrutinibDrug
Administered orally
PlaceboDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1-Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationTime frame: Baseline Up to Week 4
- Phase 1-Dose Limiting Toxicity (DLT) of PirtobrutinibTime frame: Baseline Up to Week 4
- Phase 1-Number of Participants with Treatment-Related Adverse Events as Assessed by Vital Signs: Blood Pressure, Pulse Rate, and Body TemperatureTime frame: Baseline Up to Week 16
- Phase 1-Number of Participants with Treatment-Related Adverse Events as Assessed by Clinical Lab Tests: Hematology, Clinical Chemistry, Urinalysis, Pregnancy, Hepatitis Serology and Cytomegalovirus (CMV)Time frame: Baseline Up to Week 16
- Phase 1-Number of Participants with Treatment-Related Adverse Events as Assessed by Electrocardiograms (ECGs): ECG QT IntervalTime frame: Baseline Up to Week 16
- Phase 2-Efficacy of Pirtobrutinib Versus PlaceboTime frame: Baseline Up to Week 24
Locations
43 sites in 10 countries. Site status is shown where the registry gives one.
USC Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
Stanford University
Palo Alto, California · Recruiting
MedStar Georgetown University Hospital
Washington D.C., District of Columbia · Recruiting
University of Miami Hospital and Clinics Sylvester Comprehensive Cancer Center
Miami, Florida · Not yet recruiting
Bleeding and Clotting Disorders Institute
Peoria, Illinois · Not yet recruiting
Ochsner Clinic Foundation
New Orleans, Louisiana · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
Texas Oncology - Central South
Austin, Texas · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Texas Oncology Gulf Coast
The Woodlands, Texas · Recruiting
Nanfang Hospital of Southern Medical University
Guangzhou, China · Recruiting
Qilu Hospital of Shandong University
Jinan, China · Recruiting
Hematology Hospital of the Chinese Academy of Medical Sciences
Tianjin, China · Not yet recruiting
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, China · Recruiting
OUH
Odense C, Denmark · Recruiting
Hôpital Henri Mondor
Créteil, France · Recruiting
CHU Dijon - Hopital du Bocage
Dijon, France · Recruiting
Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS
Bologna, Italy · Recruiting
Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
Milan, Italy · Recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, Italy · Recruiting
Azienda Sanitaria Universitaria Giuliano Isontina (ASU GI)
Trieste, Italy · Recruiting
Haukeland University Hospital
Bergen, Norway · Recruiting
Sykehuset Ostfold, Kalnes
Grålum, Norway · Recruiting
St. Olavs Hospital Hf, Universitetssykehuset i Trondheim
Trondheim, Norway · Recruiting
Pratia Onkologia Katowice
Katowice, Poland · Recruiting
Pratia MCM Krakow
Krakow, Poland · Recruiting
Aidport sp z o.o.
Skorzewo, Poland · Recruiting
MICS Centrum Medyczne Torun
Torun, Poland · Recruiting
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu
Wroclaw, Poland · Not yet recruiting
Pusan National University Hospital
Busan, South Korea · Recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Severance Hospital, Yonsei University Health System
Seoul, South Korea · Recruiting
Asan Medical Center
Seoul, South Korea · Recruiting
The Catholic University of Korea, Seoul St. Mary's Hospital
Seoul, South Korea · Recruiting
Hospital Clinic de Barcelona
Barcelona, Spain · Recruiting
Hospital Universitario de Burgos
Burgos, Spain · Recruiting
Hospital General Universitario Morales Meseguer
Murcia, Spain · Recruiting
Clinica Universidad de Navarra
Pamplona, Spain · Recruiting
Bristol Haematology and Oncology Centre
Bristol, United Kingdom · Recruiting
St James's University Hospital
Leeds, United Kingdom · Recruiting
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.